Brief: MBX Biosciences Announces Positive Phase 1 Topline Results For MBX 1416 To Treat Post-Bariatric Hypoglycemia
07/01/2025 12:17
Jan 7 (Reuters) - MBX Biosciences Inc MBX.O :
* MBX BIOSCIENCES ANNOUNCES POSITIVE PHASE 1 TOPLINE RESULTS
FOR
MBX 1416 FOR THE TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA
* MBX BIOSCIENCES INC - 1416 GENERALLY WELL-TOLERATED WITH
FAVORABLE SAFETY PROFILE
* MBX BIOSCIENCES - PENDING ALIGNMENT WITH FDA, PHASE 2
STUDY OF
MBX 1416 IN PATIENTS WITH PBH ANTICIPATED IN SECOND HALF OF 2025
Source text: ID:nGNX8myvpJ
Further company coverage: MBX.O
((Reuters.Brief@thomsonreuters.com))
Recent news on MBX Biosciences
See all newsU.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC Solutions
MBX Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: MBX Biosciences Announces Executive Leadership Transition To Support The Company’S Next Phase Of Growth
MBX Biosciences falls after executive shakeup
U.S. STOCKS ON THE MOVE-SpaceX, Tesla, Woodside Energy Group